DiaMedica Therapeutics Inc.
DMAC
$5.86
-$0.17-2.82%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 8.52M | 8.05M | 7.62M | 7.85M | 7.83M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 31.45M | 29.08M | 26.68M | 24.11M | 22.38M |
Operating Income | -31.45M | -29.08M | -26.68M | -24.11M | -22.38M |
Income Before Tax | -29.55M | -26.97M | -24.41M | -21.66M | -19.86M |
Income Tax Expenses | 28.00K | 29.00K | 30.00K | 43.00K | 43.00K |
Earnings from Continuing Operations | -29.58 | -27.00 | -24.44 | -21.71 | -19.90 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -29.58M | -27.00M | -24.44M | -21.71M | -19.90M |
EBIT | -31.45M | -29.08M | -26.68M | -24.11M | -22.38M |
EBITDA | -31.42M | -29.04M | -26.64M | -24.07M | -22.35M |
EPS Basic | -0.69 | -0.65 | -0.60 | -0.55 | -0.52 |
Normalized Basic EPS | -0.43 | -0.40 | -0.38 | -0.34 | -0.33 |
EPS Diluted | -0.69 | -0.65 | -0.60 | -0.55 | -0.52 |
Normalized Diluted EPS | -0.43 | -0.40 | -0.38 | -0.34 | -0.33 |
Average Basic Shares Outstanding | 171.36M | 166.47M | 161.58M | 156.79M | 151.99M |
Average Diluted Shares Outstanding | 171.36M | 166.47M | 161.58M | 156.79M | 151.99M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |